Last reviewed · How we verify
BCD-261, dose 1
At a glance
| Generic name | BCD-261, dose 1 |
|---|---|
| Also known as | anti-TL1A |
| Sponsor | Biocad |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCD-261, dose 1 CI brief — competitive landscape report
- BCD-261, dose 1 updates RSS · CI watch RSS
- Biocad portfolio CI